Business
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2021 Financial Results and Discuss Recent Business Highlights
LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, August 5, 2021
About this update from Aldeyra Therapeutics, Inc.
[{"type":"text","content":" LEXINGTON, Mass.--(BUSINESS WIRE)--\nAldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, August 5, 2021 to report financial results for the quarter ended June 30, 2021 and discuss recent business highlights.\n\nThe dial-in numbers are (866) 211-4098 for domestic callers and (647) 689-6613 for international callers. The Conference ID number is 4968588. A live webcast of the conference call will also be available on the Investors & Media page of the company’s corporate website at https://ir.aldeyra.com.\n\nAfter the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.\n\nAbout Aldeyra Therapeutics, Inc.\n\nAldeyra Therapeutics is a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases. Two of the company’s lead product candidates, reproxalap and ADX-629, target RASP, which are pre-cytokine, systems-based mediators of inflammation. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191 (methotrexate for intravitreal injection), a drug candidate in Phase 3 testing for the prevention of proliferative vitreoretinopathy. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210729005551/en/\n\nCorporate Contact:\nJoshua Reed\nAldeyra Therapeutics, Inc.\nTel: 781-761-4904 ext. 218\[email protected]\n\nInvestor & Media Contact:\nScott Solomon\nSharon Merrill Associates, Inc.\nTel: 617-542-5300\[email protected]\n\nSource: Aldeyra Therapeutics, Inc.","length":4571,"tagName":"div"}]